Synergy Pharmaceuticals (FRA:S90) Total Liabilities : €153.65 Mil (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals Total Liabilities?

Synergy Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2018 was €153.65 Mil.

Synergy Pharmaceuticals's quarterly Total Liabilities declined from Mar. 2018 (€138.91 Mil) to Jun. 2018 (€138.07 Mil) but then increased from Jun. 2018 (€138.07 Mil) to Sep. 2018 (€153.65 Mil).

Synergy Pharmaceuticals's annual Total Liabilities declined from Dec. 2015 (€157.11 Mil) to Dec. 2016 (€49.59 Mil) but then increased from Dec. 2016 (€49.59 Mil) to Dec. 2017 (€145.45 Mil).

Synergy Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Synergy Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synergy Pharmaceuticals Total Liabilities Chart

Synergy Pharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Liabilities

Get a 7-Day Free Trial

12.56

167.20

157.11

49.59

145.45

Synergy Pharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Total Liabilities	Get a 7-Day Free Trial															123.72	145.45	138.91	138.07	153.65

Synergy Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Synergy Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	32.234	+	(97.988	+	15.223
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	145.45

Total Liabilities	=	Total Assets (A: Dec. 2017 )	-	Total Equity (A: Dec. 2017 )
	=	140.782	-	-4.663
	=	145.45

Synergy Pharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2018 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	135.344	+	(0	+	8.673
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	9.629	+	0)
	=	153.65

Total Liabilities	=	Total Assets (Q: Sep. 2018 )	-	Total Equity (Q: Sep. 2018 )
	=	71.164	-	-82.481
	=	153.65

Synergy Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Synergy Pharmaceuticals (FRA:S90) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170

Website

http://www.synergypharma.com

Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines